The Asia Pacific Onychomycosis Market would witness market growth of 5.6% CAGR during the forecast period (2022-2028).
Onychomycosis is frequently thought of as merely a cosmetic issue. However, it can be unpleasant, cause cellulitis in elderly people, and can result in foot ulcers in diabetic patients. The key to enhancing the appearance and preventing these consequences is the eradication of the infection. But this is difficult to do because keratin, the substance that makes up nails and is nonvascular and impervious to many substances, makes it difficult to do. As a result, topical and oral medications are mostly preferred to treat the condition.
The type of treatment depends on the organism involved, how severe the nail alterations are, and any potential side effects or drug interactions. On the basis of cure characteristics that are specified differently between researches, treatments also range in their effectiveness. Recurrent infection is possible even for those who seem to be treated, and it can happen for various reasons. Concomitant disease, genetics, immunosuppression, improper dosage or course of therapy, dampness, occlusive footwear, advanced age, poor cleanliness, tinea pedis, and trauma are some major risk factors.
Controlling the transmission of infectious diseases, such as HIV, continues to be difficult in many Asian countries. New illnesses and drug-resistant forms of health issues are particularly prone to spreading in Southeast Asia. Asia, where over two-thirds of the world's poor reside, nevertheless experiences food insecurity. Southeast Asia is experiencing rapid changes in its population, agriculture, and food systems, which have led to an increase in the development of common infections resistant to last-resort antibiotics. Therefore, in the coming years, the demand for onychomycosis treatment would increase, which will expedite the growth of the regional market.
The China market dominated the Asia Pacific Onychomycosis Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $328.1 Million by 2028. The Japan market is estimated to grow a CAGR of 5% during (2022 - 2028). Additionally, The India market would experience a CAGR of 6.3% during (2022 - 2028).
Based on Type, the market is segmented into Distal Subungual, Proximal Subungual, White Superficial and Others. Based on Treatment, the market is segmented into Topical, Oral and Others. Based on countries, the market is segmented into China, Japan, India, Australia, South Korea, Singapore, and Rest of Asia Pacific.
Free Valuable Insights: The Worldwide Onychomycosis Market is Projected to reach USD 4.5 Billion by 2028, at a CAGR of 4.8%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Pfizer, Inc., Teva Pharmaceuticals Industries Ltd., Abbott Laboratories, Bausch Health Companies, Inc., Bayer AG, Cipla Limited, Merck & Co., Inc., Novartis AG, Sun Pharmaceutical Industries Ltd., and GlaxoSmithKline PLC.
By Type
By Treatment
By Country
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 